Approval Alert: Apotex and Sam Chun Dang Announce Canadian Approval of Biosimilar Aflibercept
On 2 July 2025, Apotex announced that Aflivu™, biosimilar to Regeneron/Bayer’s Eylea® (aflibercept, 2mg), has been approved by Health Canada in…
Pearce IP is Australia and New Zealand’s leading life sciences-focused intellectual property law firm.
Supporting life sciences clients from early-stage R&D through to commercial launch and beyond.
pearceIP.law | [email protected] | +61 2 9023 9988 | +64 4 886 1199
Popular articles from this firm
